Inovio’s experimental Covid-19 vaccine produces antibodies in mice and guinea pigs
The US immunotherapy company says preliminary results from its human trial, using 40 healthy participants, are expected in June
20 May 2020 - 17:52
Bengaluru — US immunotherapy company Inovio Pharmaceuticals said on Wednesday that its experimental vaccine to prevent coronavirus infection produced protective antibodies and immune system responses in mice and guinea pigs.
The company’s shares, which have more than quadrupled this year on hopes of its vaccine working, surged another 18% to $15.77 early trading...
Would you like to comment on this article?
Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Commenting is subject to our house rules.
BL Premium
This article is reserved for our subscribers.
A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.
Already subscribed? Simply sign in below.
Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now